Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer

Tarrik M. Zaid, Tsz Lun Yeung, Melissa S. Thompson, Cecilia S. Leung, Tom Harding, Ngai Na Co, Rosie S. Schmandt, Suet Ying Kwan, Cristian Rodriguez-Aguay, Gabriel Lopez-Berestein, Anil K. Sood, Kwong Kwok Wong, Michael J. Birrer, Samuel C. Mok

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

Purpose: To evaluate the prognostic value of fibroblast growth factor receptor 4 (FGFR4) protein expression in patients with advanced-stage, high-grade serous ovarian cancer, delineate the functional role of FGFR4 in ovarian cancer progression, and evaluate the feasibility of targeting FGFR4 in serous ovarian cancer treatment. Experimental Design: Immunolocalization of FGFR4 was conducted on 183 ovarian tumor samples. The collected FGFR4 expression data were correlated with overall survival using Kaplan-Meier and Cox regression analyses. The effects of FGFR4 silencing on ovarian cancer cell growth, survival, invasiveness, apoptosis, and FGF1-mediated signaling pathway activation were evaluated by transfecting cells with FGFR4-specific siRNAs. An orthotopic mouse model was used to evaluate the effect of injection of FGFR4- specific siRNAs and FGFR4 trap protein encapsulated in nanoliposomes on ovarian tumor growth in vivo. Results: Overexpression of FGFR4 protein was significantly associated with decreased overall survival durations. FGFR4 silencing significantly decreased the proliferation, survival, and invasiveness and increased apoptosis of ovarian cancer cells. Also, downregulation of FGFR4 significantly abrogated the mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB), and WNT signaling pathways, which are activated by FGF1. Targeting FGFR4 with the FGFR4-specific siRNAs and FGFR4 trap protein significantly decreased ovarian tumor growth in vivo. Conclusions: FGFR4 is a prognostic marker for advanced-stage, high-grade serous ovarian carcinoma. Silencing FGFR4 and inhibiting ligand-receptor binding significantly decrease ovarian tumor growth both in vitro and in vivo, suggesting that targeting ovarian cancer cells with high levels of FGFR4 protein expression is a new therapeutic modality for this disease and will improve survival of it.

Original languageEnglish (US)
Pages (from-to)809-820
Number of pages12
JournalClinical Cancer Research
Volume19
Issue number4
DOIs
StatePublished - Feb 15 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Zaid, T. M., Yeung, T. L., Thompson, M. S., Leung, C. S., Harding, T., Co, N. N., Schmandt, R. S., Kwan, S. Y., Rodriguez-Aguay, C., Lopez-Berestein, G., Sood, A. K., Wong, K. K., Birrer, M. J., & Mok, S. C. (2013). Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clinical Cancer Research, 19(4), 809-820. https://doi.org/10.1158/1078-0432.CCR-12-2736